Polyrizon Shares Flat After Delay in New Filing Near Highs
Polyrizon shares closed at $16.50, unchanged, with trading volume more than double the average. The company named Ami Oren as a Class I director, effective May 14, according to an SEC filing. No new clinical or financial updates were announced. Polyrizon’s NASARIX nasal spray remains in pre-trial development.